Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Aurobindo Pharma LLC...

    Aurobindo Pharma LLC recalls over 1.5 million injections from

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-05-12T09:05:57+05:30  |  Updated On 12 May 2018 9:05 AM IST
    Aurobindo Pharma LLC recalls over 1.5 million injections from

    Hyderabad: Auromedics Pharma LLC,a US subsidiary of Aurobindo Pharma, has initiated voluntary recall of over 1.5 million bags of different anti biotic and anti-seizure injections from the US market due to "lack of assurance of sterility."


    According to a notification put up by the US Food and Drug Administration on its website, the recalls have been initiated by the firm under 'Class-II' classification.


    The company started recalling nearly 0.4 million bags of Linezolid Injection 600 mg per 300 mL (2 mg/mL) For Intravenous Administration, 0.67 million bags levo floxacin in 5 % Dextrose Injection of different strengths and0.52 million of Levetiracetam of different strengths, for the same reason, as per the notification.


    Levetiracetam is used in combination with other medications to treat certain types of seizures in adults and children with epilepsy while Linezolidand Levofloxacinare used to treat infections.


    "Lack of assurance of sterility'; confirmed customer report of a leaking bag and mold found between the outer bag and the overwrap,"the FDA said as reason for the recall.


    According to the US health regulator, Class II recall is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.


    The injections were manufactured by Aurobindo Pharma Limited at its Pashamylaram plant in Telangana for Auro Medics Pharma.


    "Healthcare professionals patients and consumers who have the product lot which is being recalled should immediately stop using and return to place of purchase/contact their doctor as appropriate," FDA cautions in case of a recall.

    anti bioticanti-seizureAuro Medics PharmaAurobindo PharmaDextrose InjectionFDAhealth careinjectionsLevetiracetamlevo floxacinLinezolid InjectionLLCPashamylaram plant
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok